Nirmidas Biotech, Inc., a Palo Alto, CA-based diagnostic research technology company, raised $2m in seed round funding.
Backers included a prominent venture capital firm, a life science angel investor, and the Stanford-StartX Fund.
The company intends to use the funds to commercialize its fluorescence enhancing plasmonic gold technology, called “pGOLD”.
Led by Dr. Hongjie Dai, scientific co-founder and Chaired Professor of Chemistry at Stanford, and Dr. Meijie Tang, CEO and Co-founder, Nirmidas provides solutions for bio-analytical and diagnostic researchers using plasmonic gold (pGOLD) technology that enhances near-infrared fluorescence signal, optimized over nearly a decade of research at Stanford University.
The company is a resident at Janssen Labs @QB3 as well as StartX Med, a Stanford-affiliated nonprofit technology accelerator program.